Physician profile
Raminder Parihar
NPI 1952689168
$3,246.16
in general payments reported to CMS, 2019-2025
24 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $281 · 2021: $332 · 2022: $388 · 2023: $361 · 2024: $780 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,098.88 | 2019-2024 | General - Dbs, Vercise |
| Medtronic USA, INC. | $417.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $298.20 | 2020-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $252.09 | 2021-2024 | |
| Kyowa Kirin, INC. | $202.57 | 2020-2024 | Nourianz |
| Abbott Laboratories | $143.29 | 2021-2025 | Infinity |
| Biogen, INC. | $115.33 | 2025 | |
| Medtronic, INC. | $98.89 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $96.18 | 2019-2020 | |
| Allergan, INC. | $78.41 | 2020-2021 | |
| Lundbeck LLC | $72.58 | 2019-2020 | |
| Pfizer INC. | $71.93 | 2021 | |
| Vertical Pharmaceuticals, LLC | $70.28 | 2019 | |
| Grifols USA, LLC | $49.56 | 2023-2024 | Gamunex-C |
| Neurocrine Biosciences, INC. | $41.14 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.97 | 2019 | |
| Acorda Therapeutics, INC | $22.68 | 2019 | |
| Avion Pharmaceuticals | $21.65 | 2022 | |
| Csl Behring | $21.16 | 2024 | Hizentra |
| Amneal Pharmaceuticals LLC | $17.75 | 2025 | Crexont |
| Alexion Pharmaceuticals, INC. | $16.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.13 | 2025 | Dysport |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raminder Parihar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.